RxDoctor Payments Data

Tam le, MD

Internal Medicine · Garden Grove, CANPI 1336381607

Payments from drug & device makers

$1,976in general payments, 2019–2025

Across 42 payments — averaging $47.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1000
  • Novo Nordisk$405
  • Boehringer Ingelheim$270
  • AbbVie$140
  • Gilead$96
  • Lilly USA, LLC$25
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$1,96399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen18$1,000
Novo Nordisk9$405
Boehringer Ingelheim3$270
AbbVie8$140
Gilead1$96
Lilly USA, LLC1$25
Johnson & Johnson1$24
Abiomed1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,976 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$60,892
Medicare patients
122
Services billed
593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin83$73,858
TrulicityDulaglutide25$26,747
VascepaIcosapent Ethyl79$26,041
RybelsusSemaglutide19$21,832
JanuviaSitagliptin Phosphate29$19,954
RestasisCyclosporine23$18,059
Diclofenac Sodium33$13,364
Cyclosporine27$10,103
CreonLipase/Protease/Amylase12$9,491
EliquisApixaban17$8,915
XiidraLifitegrast14$8,571
SynjardyEmpagliflozin/Metformin Hcl13$7,727
Icosapent Ethyl35$5,361
Ranolazine ErRanolazine11$2,232
Atorvastatin Calcium258$1,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$270$81,58496 claims
AbbVieRestasis, Creon$140$27,55135 claims
Lilly USA, LLCTrulicity$25$26,74725 claims
Novo NordiskRybelsus$405$21,83219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →